CCR2/5-inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CCR2/5-inhibitor, covering 2025-01-17 to 2025-01-17. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) [Phase 2]